Fox Run Management, L.L.C. Natera, Inc. Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$85.28 - $112.6 $317,071 - $418,646	-3,718 Reduced 64.53%	2,044 $221,000
Q1 2024 May 13, 2024	SELL	$59.21 - $92.9 $144,650 - $226,954	-2,443 Reduced 29.77%	5,762 $526,000
Q4 2023 Feb 13, 2024	SELL	$37.55 - $62.64 $11,227 - $18,729	-299 Reduced 3.52%	8,205 $513,000
Q3 2023 Nov 07, 2023	BUY	$43.4 - $62.52 $369,073 - $531,670	8,504 New	8,504 $376,000
Q3 2022 Nov 07, 2022	SELL	$36.93 - $56.68 $166,185 - $255,060	-4,500 Reduced 33.46%	8,948 $392,000
Q2 2022 Aug 12, 2022	BUY	$28.13 - $44.54 $204,758 - $324,206	7,279 Added 117.99%	13,448 $477,000
Q1 2022 May 10, 2022	BUY	$30.32 - $91.33 $187,044 - $563,414	6,169 New	6,169 $251,000

526

119M

308K

191K

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $16.2B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.